...

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Private Advisor Group LLC



Private Advisor Group LLC has increased its stake in Elanco Animal Health Incorporated (New York Stock Exchange: ElanFree report) rose 9.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The company owns 148,087 shares of the company’s stock after purchasing an additional 13,185 shares during the quarter. Private Advisor Group LLC’s holdings in Elanco Animal Health were valued at $2,206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new stake in Elanco Animal Health in the third quarter valued at approximately $95,000. CM Bidwell & Associates Ltd. Acquired a new stake in shares of Elanco Animal Health in the third quarter valued at approximately $129,000. Innovis Asset Management LLC purchased a new stake in shares of Elanco Animal Health during the third quarter worth approximately $144,000. Ieq Capital LLC raised its stake in Elanco Animal Health by 10.8% in the 3rd quarter. Ieq Capital LLC now owns 13,464 shares of the company’s stock valued at $151,000 after purchasing an additional 1,311 shares during the last quarter. Finally, HBK Sorce Advisory LLC purchased a new position in Elanco Animal Health in the 4th quarter valued at $169,000. Hedge funds and other institutional investors own 97.48% of the company’s shares.

Insider activity

In other animal health news from Elanco, Director R. David Hoover It acquired 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $16.14 per share, for a total value of $322,800.00. Following the transaction, the director now owns 185,000 shares of the company’s stock, valued at $2,985,900. The deal was disclosed in a filing with the Securities and Exchange Commission, which is available at this link. Corporate insiders own 0.57% of the company’s shares.

Analysts set new price targets

A number of equity research analysts have recently issued reports on the stock. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. Barclays raised their price target on shares of Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a research note on Thursday. Goldman Sachs Group raised their price target on shares of Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley raised their target price on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a “Moderate Buy” consensus rating and a consensus price target of $17.29.

Check out the latest Elanco Animal Health stock report

Elanco animal health stock fell 1.2%

shares Elan stock It opened at $17.00 on Monday. The company’s 50 day moving average is $15.02 and its two-hundred day moving average is $14.18. Elanco Animal Health Incorporated has a 12 month low of $7.88 and a 12 month high of $17.43. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (New York Stock Exchange: ElanGet a free report) released its latest quarterly earnings data on Wednesday, May 8. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The company achieved revenues of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The company’s quarterly revenue fell 4.1% year over year. During the same period of the previous year, the company achieved earnings of $0.45 per share. Equities research analysts expect that Elanco Animal Health Incorporated will post 0.92 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

(Free report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. Offers pet health disease prevention products, such as parasiticides and vaccine products that protect pets from worms, fleas and ticks under the Seresto, Advantage, Advantix and Advocate brands; pet health treatments for pain, osteoporosis, ear infections, cardiovascular diseases, and skin conditions in canines and cats under the Galliprant and Claro brands; Vaccines, antibiotics, parasiticides, and other products used in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; A range of vaccines, antibiotics, implants, parasiticides and other products used in the production of ruminants and pigs under the brands Rumensin and Baytril.

In-depth reading

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com For the latest 13F filings and insider deals for Elanco Animal Health Incorporated (New York Stock Exchange: ElanFree report).

Institutional Ownership Quarterly for Elanco Animal Health (NYSE:ELAN)



Get Elanco Animal Health news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Elanco Animal Health and related companies MarketBeat.com’s free daily email newsletter.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

Back to top button

Adblock Detected

PLZ DISABLE YOUR ADBLOCK AND REFRESH THE PAGE